Future Medical Device Companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies

STXS 2.925

-0.2%

1:48 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: IRWIN JAMES FRANKEL	2/4/2008 5:20:12 PM
	Read Replies (1) of 136

Goldman Sachs analyst Lawrence Keusch cut his six-month price target on the stock to $8 per share from $15, saying he did not think delays in the catheter's approval would have such a large impact on the company's sales. "Although management had indicated in the past that the delay in approval for the irrigated catheter could undermine previously established 2007 guidance, the substantially worse-than-expected fourth quarter results are likely to raise questions regarding hospital discretionary spending patterns and/or competitive dynamics," he said. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next